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Abstract 24
A common outcome of antibiotic exposure in patients and in vitro is the evolution of a 25 hypermutator phenotype that enables rapid adaptation by pathogens. While hypermutation is a 26 robust mechanism for rapid adaptation, it requires trade-offs between the adaptive mutations and 27 the more common "hitchhiker" mutations that accumulate from the increased mutation rate. 28
Using quantitative experimental evolution, we examined the role of hypermutation in driving 29 adaptation of Pseudomonas aeruginosa to colistin. Metagenomic deep sequencing revealed 30 2,657 mutations at > 5% frequency in 1,197 genes and 761 mutations in 29 end point isolates. By 31 combining genomic information, phylogenetic analyses, and statistical tests, we showed that 32 evolutionary trajectories leading to resistance could be reliably discerned. In addition to known 33 alleles such as pmrB, hypermutation allowed identification of additional adaptive alleles with 34 epistatic relationships. Although hypermutation provided a short-term fitness benefit, it was 35 detrimental to overall fitness. Alarmingly, a small fraction of the colistin adapted population 36 remained colistin susceptible and escaped hypermutation. In a clinical population, such cells 37 could play a role in re-establishing infection upon withdrawal of colistin. We present here a 38 framework for evaluating the complex evolutionary trajectories of hypermutators that applies to 39 both current and emerging pathogen populations. 40
Importance 41
Bacteria can increase mutation rates in response to stress as an evolutionary strategy to avoid 42 extinction. However, the complex mutational landscape of hypermutators makes it difficult to 43 distinguish truly adaptive mutations from hitchhikers that follow similar evolutionary 44 trajectories. We provide a framework for evaluating the complex evolutionary trajectories of 45 hypermutators that can be applied to both current and emerging pathogen populations. Using 46 than non-hypermutators. Interestingly, the dramatic increase in mutation rate also means that 70 many non-adaptive mutations accumulate and are carried along as "hitchhikers" that in the long 71 run are likely to decrease the overall fitness of the organisms in non-selective conditions (18, 72 19 ). Nevertheless, hypermutation provides a swift strategy for cells undergoing stress to acquire 73 adaptive mutations before they go extinct. 74
Experimental evolution is a powerful approach to understanding the genetic and 75 biochemical basis for antibiotic resistance (16, (20) (21) (22) (23) (24) (25) . In this work, P. aeruginosa PAO1 was 76 evolved to colistin as a continuous culture in a bioreactor where the population was constantly 77 maintained at mid-exponential phase in the presence of sub-inhibitory drug concentrations (24) . 78
The observation of hypermutation, accompanied by a dramatic increase in mutation rate among 79 the evolving PAO1 population presented both challenges and opportunities for understanding the 80 evolution of colistin resistance. The potential benefits of this complex data set, however, were 81 equally clear. Hypermutation generated an extensive, if not nearly exhaustive survey of the 82 accessible evolutionary trajectories leading to colistin resistance. 83
We used a combination of phylogenetic and statistical approaches to sort through these 84 complex data, discern truly adaptive alleles from hitchhikers and infer not just the major genetic 85 changes associated with colistin resistance but also those alleles that, in combination with the 86 major players were essential to produce the high minimum inhibitory concentrations (MICs) 87 observed in many clinical isolates (12, 26) . Our work has benefited strongly from a series of 88 clinical and in vitro experimental evolution studies that have identified many of the major 89 contributors to colistin resistance in P. aeruginosa (10, 12, 13, 26, 27) . 90
Taken together, our work provides a comprehensive survey of the alleles responsible for 91 P. aeruginosa resistance to colistin and perhaps, more importantly, a means to examine future 92 hypermutators in less well characterized or emerging pathogens. The increased mutation rate of 93 hypermutators provides a major adaptive advantage to this pathogen during exposure to colistin. 94
This highlights the strength of hypermutation as an adaptive strategy during exposure to stress 95 and the adaptability of P. aeruginosa to survive under such conditions, making it a formidable 96 pathogen. 97
98
Results 99
Hypermutator variants of P. aeruginosa emerge rapidly after colistin exposure during 100 continuous experimental evolution 101 P. aeruginosa PAO1 was evolved to colistin as a continuous culture in a bioreactor using 102 quantitative experimental evolution (24). The starting MIC of colistin for PAO1 was 1-2 mg/l. 103
Over the course of experiment, the PAO1 population was exposed to increasing, but sub-104 inhibitory, concentrations of colistin to a final concentration of 16 mg/l colistin, which is four 105 times higher than the clinical breakpoint for resistance of P. aeruginosa to colistin (MIC > 106 4mg/l) (28). Genomic DNA from each daily population was prepared for metagenomic deep 107 sequencing. At the end of the experiment, the final population was serially diluted and spread on 108 a non-selective growth medium for the isolation of end point isolates for whole genome 109 sequencing. The end point isolates produced colonies of diverse morphologies (Supplementary 110 file S1) consistent with the selection of a highly polymorphic population within the bioreactor 111 experiments and this was consistent across duplicate experiments. Single colonies isolated from 112 the final populations ranged from being totally susceptible to totally resistant to colistin which is 113 also consistent with a diverse polymorphic population ( Fig. S1 (b) and Table S1 ). 29 end point 114 isolates were selected for whole genome sequencing. 115
Of the 29 sequenced isolates, 25 contained mutations within mutS, the gene encoding the 116 DNA mismatch repair enzyme MutS (Fig. 1 ). Those end point isolates that had acquired mutS 117 mutations had from 44 to 92 mutations each while strains without mutations in mutS had 5 to 9 118 mutations showing that mutations within mutS correlated with increased genetic diversity. 119
Metagenomic deep sequencing of daily populations showed that on day 10 of adaptation during 120 both, runs 1 and 2 (corresponding to 1.75 mg/l colistin in run 1 and 2 mg/l colistin in run 2), 121 mutations were observed readily in mutS ( Fig. 1 ). While the majority of the population contained 122 mutations within mutS, a fraction of the final population did not become hypermutators (14.6% 123 in run 1 and 7.6% in run2). 124
As expected, the acquisition of the mutS mutations was accompanied by a rapid increase 125 in mutation frequency in the total evolving population. As seen in Figure 2 , the starting 126 population on day 1 of evolution, in both runs, had a basal level of diversity. Aside from the 127 underlying diversity in the population, what is apparent from Figure 2 is that as soon as mutS 128 mutations arose in both the evolving populations (indicated by red stars), the populations started 129 accumulating more mutations that rose to higher frequencies than mutations contributing to the 130 basal diversity in the population. This was accompanied by increased non-susceptibility of the 131 total population to colistin. Interestingly, lineages derived from Run 1 mutS with a 1 bp deletion 132 that introduces a premature stop codon at residue 609 and Run 2 mutS with a 10 bp deletion that 133 alters the last 16 amino acids both go to extinction, demonstrating that hypermutation, while 134 increasing the probability of finding successful evolutionary trajectories, does not guarantee 135 success. It may also be that the unsuccessful mutS mutant lineages may have stronger mutator 136 phenotypes that accumulate deleterious mutations more rapidly leading to a faster decrease in 137 overall fitness compared to the more successful mutS mutants in Runs 1 and 2. 138 Evolutionary relationship of end point isolates highlights the role of secondary mutations in 139 resistance 140
Phylogenetic trees were constructed to identify the linkages of mutations within the end 141 point isolates (Fig. 3) . The 29 sequenced end point isolates had cumulatively acquired 761 total 142 mutations affecting 563 genes. It was interesting to note that in both adaptation runs, isolates that 143 did not acquire mutS mutations were phylogenetically closely related to the ancestor and had no 144 increase in colistin resistance. The lack of success in achieving high levels of colistin tolerance 145 by the non-hypermutators highlights the higher efficiency of sampling the potential evolutionary 146 trajectories by strains with elevated mutation rates. End point isolates containing mutS mutations 147 had undergone considerable divergence, with each branch varying substantially in total number 148 and type of mutations. It was evident that being a hypermutator alone was not sufficient to 149 acquire resistance. Isolates like I1-6 and I1-76 that had MutS L142P were still susceptible (MIC = 2 150 mg/l) and thus while mutations to mutS are drivers for adaptation they are not directly 151 responsible for increased colistin resistance. 152
The highest levels of resistance were achieved by end point isolates that emerged from 153 branches containing mutations in the pmrAB genes. Previous studies in P. aeruginosa have 154 identified the role of PmrAB in resistance to cationic antimicrobial peptides (CAPs) (29, 30). In 155 This suggested that although mutations in pmrAB were required for achieving resistance, 159 additional mutations in resistant end point isolates were playing an essential role in increasing 160 resistance to colistin. 161
Hypermutation reveals challenges in distinguishing adaptive mutations from hitchhikers 162
As the final populations of experimental evolution were dominated by cells with mutator 163 phenotypes, classical genetic approaches for the validation of adaptive alleles such as 164 reintroducing the proposed changes into a clean genomic background were effectively 165 impossible (with an average of 60 mutations per hypermutator end point isolate, there were 60! 166 possible combinations of mutations) and required a different approach. While hypermutation 167 introduced a large number of non-adaptive hitchhiker alleles into both the metagenomic and end 168 point isolate genomic data, the extensive mutational saturation offered a methodological path 169 forward. A statistical approach was used to identify potentially adaptive genes based on the 170 concept that if a larger than expected number of mutations in the same gene across various end 171 point isolates from both the runs were identified then those genes were more likely to be adaptive 172 (16) . Under the null hypothesis that all mutations were randomly distributed across the genome, 173 11 genes were identified that were mutated more frequently than expected in the end point 174 isolates using the Fisher's Exact Test (Table 1) . A total of 563 genes were mutated in the 29 175 sequenced end point isolates. By plotting the number of mutations per gene versus the 176 percentage of end point isolates having a mutation in that gene ( Fig. 4) , it was observed that 177 some of the statistically significant genes (p value < 0.001) were located on the top right 178 quadrant. The exception to this was mutS. Although mutS was seen in 25 of the 29 sequenced 179 end point isolates that have a total of 3 unique mutations in this gene, the mutS gene itself was 180 sufficiently long (2568 bp) so that it did not meet the p value cut-off of 0.001 for being called 181 significant. If a gene is very long or if a single mutation or small subset of mutations are the only 182 possible adaptive changes in that gene then it may not rise above the required p value according 183 to the Fisher's Exact Test. This highlights a shortcoming of this particular approach and explains 184 why we combine it with other methods (discussed later) to increase the overall success in 185 identifying adaptive alleles. 186
Among the evolving daily populations from both runs, 1,197 genes were mutated and a 187 total of 2657 mutations were identified at > 5% frequency. When this same test was performed 188 on these mutations, 41 genes were identified as significant (Table 2) . Among these 41 genes, 189 four were also identified in the Fisher's Exact Test of the end point isolates (pmrB, PA0011, 190 migA and pslA). pmrA, which is known to be involved in resistance, was not identified as a 191 significant gene in the end point isolates but was in the daily populations. The power of this test 192 could certainly be increased by having data from multiple evolving populations instead of the 2 193 runs conducted in this work. Taken together however, the cumulative data from the 2 populations 194 and 29 end point isolates provides an extensive list of genes that potentially play a role in colistin 195 resistance. 196
Identification of additional genes associated with colistin resistance 197
Previous studies have been conducted to identify genetic changes leading to polymyxin 198 resistance in P. aeruginosa (11-13, 26, 27, 30-32). Since resistance has been often associated 199 with hypermutation (12, 13) which leads to accumulation of a large number of non-adaptive, 200 hitchhiker mutations, not all mutations can be implicated in resistance. However, if the same 201 gene is mutated during adaptation to polymyxin in different studies that use different 202 experimental conditions, it is more likely an adaptative allele than a hitchhiker. We identified 203 such genes that were found to be mutated in our study as well as previous studies and arranged 204 them in the following functional groups: two component system, pmrAB, lipopolysaccharide 205 modification and biosynthesis genes (migA, pagL and PA5194), long chain fatty acid CoA-ligase 206 (fadD2), outer membrane protein (opr86), probable short chain dehydrogenase (PA4089) and 207 multidrug efflux transporter (mexB). While the role of some of these genes in polymyxin 208 resistance has been validated (for example, pmrAB, opr86, PA5194, pagL and mexB), others 209 have not been previously associated with resistance (12, 13, 27, 30, 33, 34) . The targets were 210 mapped on the phylogenetic trees ( Fig. 3 The number and variety of mutations observed in pmrB suggest that only modest changes 215 in PmrB function are required for increased colistin resistance 216
PmrB is the sensor kinase of a two-component system, PmrAB and is involved in sensing 217 cationic antimicrobial peptides (CAPs) (29). It was noteworthy that during the course of 218 adaptation to colistin, 19 independent mutations were detected in pmrB using a 5% frequency 219 cut-off for mutation detection. 18 of these mutations were SNPs that led to amino acid 220 modifications affecting all the domains within this protein while one mutation was a 3 bp 221 deletion leading to the loss of amino acid 47 in PmrB. Out of the 19 mutations, three (L167P, 222 L170P and F408L) were observed independently in duplicate experiments and thus, 16 unique 223 mutations were identified in pmrB. 224 isolates from previous studies (26). Allelic replacement was used to identify the role of 241 individual pmrB mutations in resistance by creating point mutations in pmrB within a wild type 242 PAO1 background. 5 such constructs were made, each containing one pmrB mutation identified 243 in the colistin evolved PAO1 populations from this work (L17P, L18P, D47G, L243R and 244 F408L). These constructs and their respective bioreactor derived end point isolates were tested to 245 compare colistin MICs (Table 3 ). Three pmrB mutations were observed in end point isolates that 246 had been selected for whole genome sequencing -L18P, L243R and F408L. Sanger sequencing 247 was used to identify the sequence of pmrB in a few other end point isolates and 2 isolates, 248 labelled as #11 and #17 were selected that had the D47G and L17P mutations in PmrB, 249
respectively. There is no information regarding other mutations in these isolates since whole 250 genomes of these isolates were not sequenced. 251
From Table 3 , it is evident that different mutations within pmrB contribute to different 252 levels of colistin resistance. While a mutation constructed in the transmembrane domain of 253 PmrB, L18P imparted complete resistance to colistin (MIC 8 mg/l), adjacent mutation L17P did 254 not (MIC 2 mg/l). The mutation L18P first appeared on day 18 of adaptation (Run 1) while L17P 255 was seen only during the final day of adaptation when the population was growing at 16 mg/l 256 colistin ( Fig. S4 ). While early mutations during adaptation are often the most beneficial, 257 additional mutations conferring typically smaller advantages can arise later (35). Appearance of 258 L18P earlier during adaptation provided resistance to members of a population that was still 259 evolving suggesting that it might be a primary mutation. L17P, which appeared later when the 260 population was already growing at a high drug concentration (16 mg/l) was not an early primary 261 mutation but may have played a role in enhancing the level of resistance in a specific genomic 262 background that had achieved initial success (12). Other point mutations in the periplasmic 263 domain (D47G), dimerization and phosphotransferase (L243R) and in the C-terminal ATP 264 binding domains (F408L) all imparted resistance to colistin with the highest MIC at 8 mg/l while 265 their corresponding bioreactor derived end point isolates consistently had acquired higher levels 266 of resistance. This data provides strong evidence for the role of epistasis in high resistance of the 267 bioreactor derived end point isolates. 268
PAO1 incurs a fitness cost as a trade-off to acquiring colistin non-susceptibility 269
Growth characteristics of the constructed mutants and bioreactor end point isolates 270 possessing the same mutation shed light on the fitness of the mutants in the presence and absence 271 of colistin (Fig. 6 ). The growth of the ancestor, PAO1 served as the reference (Fig. 6 (a) ). It was 272 clear from our data that higher levels of colistin resistance, that were associated with 273 hypermutation, led to reduced fitness in the isolates. 274 pmrB point mutants constructed in a wild type background could resist up to 8 mg/l 275 colistin without undergoing a severe growth defect in the absence of the drug. In comparison, 276 bioreactor isolates with the same pmrB mutations that had higher levels of resistance had 277 decreased fitness in the absence of the drug. Bioreactor isolate I1-37 (doubling time = 397+90 278 minutes; MIC >128 mg/l) grew more than two times slower than the point mutant PmrB L18P 279 (doubling time = 165+5 minutes; MIC = 8 mg/l) in the absence of colistin ( Fig. 6 (d) ). Isolate I1-280 37, that had 59 mutations in addition to PmrB L18P also had an increased lag time (longer by 281 approximately 125 minutes) and lower overall yield but had the ability to survive in the presence 282 of higher levels of colistin. Similarly, bioreactor isolate I2-55 (MIC = 16 mg/l) had a two-fold 283 decrease in growth rate compared to the point mutant PmrB F408L (MIC = 4 mg/l) ( Fig. 6 (f) ). 284
However, it was capable of achieving nearly the same final cell density as PmrB F408L as well as 285 the ancestor strain ( Fig. 6 (a)) suggesting that higher levels of resistance, as seen in I1-37, were 286 associated with greater fitness defects. Although PmrB L17P alone offered no adaptive advantage 287 ( Fig. 6 (a) ), bioreactor derived isolate #17 that had a very high colistin MIC also had a severe 288 growth defect. 289
The balance between acquisition of resistance and the associated fitness costs was further 290 supported by allelic replacements to produce PmrB D47G and PmrB L243R in the wild type PAO1 291 background. These adaptive mutants were only modestly less fit in terms of growth rate and 292 yield ( Fig. 6 (c), (e) and (f)) under non-selective conditions but were able to grow better than 293 wild type PAO1 in the presence of colistin which is also true for their corresponding bioreactor 294 derived end point isolates. 295
Our data suggests that while P. aeruginosa acquires myriad mutations to resist colistin, 296 the accumulation of these mutations comes at a fitness cost to the cells and higher levels of 297 resistance are usually accompanied by a more severe growth phenotype in hypermutators. The 298 advantage of mutation supply in a hypermutator is off-set by the fitness defect of the evolved 299 isolates. In spite of the fitness cost, resistance to this drug of last resort in P. aeruginosa clinical 300 isolates has been observed (36-38) which underscores the importance of understanding the 301 mechanism of colistin resistance for the design of new strategies that can circumvent this 302 problem. 303
Discussion 304
The development of a hypermutator phenotype is a common occurrence in clinical settings and 305 can lead to rapid adaptation to antibiotics (2, 14). Hypermutators increase the mutation supply 306 within the evolving population allowing natural selection to act upon a more genetically diverse 307 population thereby increasing the probability that a successful, e.g. a more antibiotic resistant 308 variant can be found (18). The increased mutation load however comes with a cost to overall 309 fitness as non-adaptive or hitchhiker mutations accumulate within the genomes of the 310 hypermutators (15). As a random mutation is much more likely to be deleterious, the 311 accumulation of these random mutations brings consequences to fitness especially when the 312 selection pressure of the antibiotic is removed. For example, end-point isolates with increased 313
MICs to colistin had substantially decreased growth rates in the absence of colistin ( Fig. 6 ). 314
While an increased mutation rate may be a poor long term evolutionary path for organisms like 315 P. aeruginosa, the short-term benefit is clear. Interestingly, in our bioreactor environments that 316 strongly favor the formation of biofilms, susceptible and non-hypermutator cells persisted 317 despite the vessel containing >2 mg/l colistin for two weeks in the case of Run 1 (Fig. 2) . We 318 speculate that the biofilms insulate these weaker variants (Supplementary file S1) and can act as 319 a reservoir for re-establishing a more fit population if the colistin were withdrawn. In an infected 320 individual such as a cystic fibrosis patient, such a reservoir could suggest that when the antibiotic 321 is switched, the more fit P. aeruginosa strains can re-emerge and conversely that colistin 322 resistant variants could now be a reservoir for re-establishing the colistin resistant population if 323 the patient returned to colistin therapy. Thus, the combination of hypermutation and strong 324 biofilms can lead to the persistent and difficult to treat infections that are a hallmark of P. 325
aeruginosa. 326
It has been suggested that because of the large number of hitchhiker mutations that 327 succeed in the population under conditions of selection, the signature of selection in the genome 328 is very weak, making it difficult to distinguish driver alleles from passenger mutations (15). We 329
show that it is possible to identify the signature of selection in an adapting hypermutator 330 population using a combination of genomic and statistical approaches. Quantitative experimental 331 evolution provides a ready means to construct the genomic data needed for analysis (13, 16, 19-332 21) . We propose a hierarchy of analyses beginning with the Fisher's Exact Test of both end-333 point isolates and longitudinal metagenomic data to build and rank a list of candidate genes that 334 are putatively involved in resistance. This method has proven useful in identification of adaptive 335 mutations in previous studies involving hypermutation and weak selection (16, 19) . We also 336 construct phylogenetic trees of the end-point isolates that provide further genetic and 337 evolutionary structure to the candidate list. Furthermore, we use the information about the 338 frequencies of these mutations in the daily populations to build parsimonious evolutionary 339 trajectories for the most important drivers for colistin resistance and taken together these 340 trajectories illustrate what we term the "adaptive genome" of P. aeruginosa to the selection 341 environment ( Fig. 7) . 342
Using genetics and phenotypic analysis of growth rates, we establish that epistatic 343 interactions between multiple mutations in the bioreactor derived hypermutator end point isolates 344 are most likely responsible for the observed higher levels of colistin resistance which comes at a 345 fitness cost to the cells in terms of reduced growth rate and overall yield ( Fig. 6 ). Such epistatic 346 interactions between multiple alleles implies that high levels of colistin resistance can be 347 acquired via multiple adaptive routes which in turn result in the formation of a rugged fitness 348 landscape with many local peaks, each representing a local optimum. Hypermutation provides an 349 effective means for the cells to access this landscape during selection. Plasmid pEX18Gm was kindly provided by Dr. Herbert Schweizer. PAO1 was routinely grown 362 in Lysogeny Broth (LB: 10 g/l tryptone, 5 g/l yeast extract, 10 g/l sodium chloride) or on LB + 363 15 g/l bacto agar. Growth medium for adaptation of PAO1 to colistin was LBHI (80% LB + 20% 364 brain heart infusion (BHI) medium) supplemented with 2 mM magnesium sulfate and 365 appropriate concentration of colistin. Colistin stock solution was made by dissolving colistin 366 sulfate (DOT Scientific Inc., MI, USA) in water followed by filter sterilization using a 0.22 µm 367 filter. Cation adjusted Mueller Hinton broth (CA-MHB) was used for minimum inhibitory 368 concentration (MIC) testing and growth curves. Gentamicin at 20 mg/l was used for maintenance 369 of pEX18Gm in Escherichia coli and 60 mg/l was used for growing PAO1 transformed with the 370 pEX18-pmrB plasmids. Strains and plasmids used in this study are listed in Table 4 . 371
Evolution of PAO1 to colistin 372 PAO1 was evolved to colistin in a modified turbidostat as described in (24). In duplicate runs, a 373 300 ml PAO1 culture was established in the bioreactor vessel by using a single colony as 374 inoculum. The culture was maintained in mid-exponential growth phase using respiratory CO2 as 375 a proxy for turbidity to control media flow. After 12 hours of growth, the first sub-inhibitory 376 dose of colistin was added to the vessel (0.5 mg/l). After that, the culture was monitored and the 377 drug concentration was empirically increased. Details of the process are provided in (24). PAO1 378 was able to grow at 18 mg/l colistin after 26 days of evolution during run 1 and at 16 mg/l 379 colistin after 17 days of evolution during run 2. 380
Isolation and characterization of end point isolates 381
The final resistant population of PAO1 was serially diluted and spread on non-selective medium 382 (LBHI + 2mM magnesium sulfate) to isolate individual members of the population. Each colony 383 was called an end point isolate. 88 end point isolates were selected from run 1 and 82 from run 2 384 for further phenotypic characterization. Morphological characteristics were recorded for each 385 isolate which included colony size, shape, color, consistency and appearance when grown in a 386 non-selective liquid medium (Supplementary file S1). Minimum inhibitory concentration (MIC) 387 of colistin was tested using a preliminary broth microdilution assay. A colistin gradient (0 to 128 388 mg/l) was set up in a 96 well polypropylene plate containing 100 µl CA-MHB per well. 1 µl of 389 an overnight culture (grown in LBHI + 2mM magnesium sulfate) for each isolate was used as 390 inoculum. Plates were incubated at 37⁰C and visible growth was recorded after 20-24 hours. The 391 lowest colistin concentration showing absence of growth was the MIC. MIC of other antibiotics 392 were also tested for determining cross-sensitivity/cross-resistance to other drugs. Agar dilution 393 MIC assays were performed for this in 100 mm petri dishes containing CA-MH agar with 394 appropriate drug concentration. A 96 pin applicator was used to spot the overnight culture of 395 each isolate on the agar plates. MICs were recorded after 20-24 hours of incubation at 37⁰C. 396
Based on the different phenotypic traits, 15 end point isolates from run 1 and 14 from run 2 were 397 selected for whole genome sequencing and mutation identification. Cross sensitivities to other 398 antibiotics were observed in some end point isolates but a correlation of the cross sensitivity to 399 colistin resistance could not be established and hence, this phenotype was not pursued further. 400
Minimum inhibitory concentration assay 401
Broth microdilution MIC tests in biological triplicate were performed for the 29 end point 402 isolates selected for whole genome sequencing using 96 well polypropylene plates. Each well 403 was filled with 100 µl CA-MHB and appropriate concentration of colistin (0-128 mg/l colistin in 404 2-fold increments). Overnight cultures for end point isolates were grown as biological triplicate 405 in LBHI + 2 mM magnesium sulfate. Optical densities of the cultures were adjusted to 0.05 and 406 5 µl of this OD adjusted culture was used to inoculate each well of the plates. Growth was 407 checked visually after 20-24 hours of incubation at 37⁰C and MICs were recorded. 408
Whole genome sequencing and analysis 409 DNA isolation and whole genome sequencing was performed as described in (24). Samples from 410 run 1 of adaptation were sequenced at the US Army Edgewood Chemical Biological Center 411 (ECBC, MD, USA) as 100 bp paired end reads and samples from run 2 were sequenced by a 412 commercial facility (Genewiz, NJ, USA) as 150 bp paired end reads. Read trimming of raw 413
Fastq reads was performed using Sickle (40). Trimmed reads were analyzed using Breseq 414 version 0.30.1 (41) to identify genetic variations between ancestor and adaptive populations as 415 well as end point isolates. The genome sequence of the ancestor was obtained from NCBI 416 (AE004091). The ancestor colony used to inoculate the bioreactor during each run was re-417 sequenced and the APPLY function on Breseq was used to incorporate any differences in the 418 genome of the re-sequenced ancestor strain into the NCBI reference genome before using it for 419 identifying mutations in the evolved strains. The consensus mode was used for identification of 420 mutations in the end point isolates. The polymorphism mode on Breseq was used for the analysis 421 of daily metagenomic populations from the bioreactor using the following command: -p --422 polymorphism-reject-surrounding-homopolymer-length 5 --polymorphism-reject-indel-423 homopolymer-length 0 --polymorphism-minimum-coverage-each-strand 6 --polymorphism-424 frequency-cutoff 0.02. To filter low quality mutations from the daily populations under analysis, 425 two additional quality-filtering steps were added after the Breseq analysis of each daily sample. 426
It was observed that the number of false calls increased substantially for low frequency 427 mutations. Thus, mutations in the daily populations that fell below a threshold of 5% frequency 428 in the population were filtered out. Second, it was found that mutations had been called in 429 several reads that had low Mapping Quality (MQ) scores. Mutations in regions that contained 430 three or more reads having an MQ score less than 100 were also filtered out. Also, reads were 431 manually examined and mutation calls which were characterized by 3 or more mutations 432 clustered within a read at low frequencies and whose occurrence was not consistent with 433 adaptation or hitchhiking were eliminated from further analysis. Dataset S1 contains a list of all 434 mutations and their frequencies on each day of evolution during Runs 1 and 2. 435
Construction of phylogenetic trees 436
The Breseq output for each end point isolate contained a list of mutations in the genome of the 437 end point isolate. The APPLY function on Breseq was used to apply the mutations in the end 438 point isolate onto the PAO1 reference genome to create a genome sequence for each end point 439 isolate. Next, the genome of the reference strain was manually aligned with that of all the end 440 point isolates using the software MEGA7 (42). Phylogenetic trees were constructed for both runs 441 using the maximum parsimony algorithm based on (43) as implemented in MEGA7. These trees 442 were then visualized using the Dendroscope3 software (44). 443
Fisher's Exact Test 444
To perform the Fisher's Exact Test on end point isolates, a list of the total number of mutations 445 occurring in a gene was compiled from the Breseq output file. Gene lengths were obtained from 446 the Pseudomonas Genome Database (45) by mapping the gene name to the gene length. A few 447 genes without matches were manually given gene lengths. With the compiled list containing the 448 number of mutations per gene, the length of the gene, the total number of mutations in all end 449 point isolates or populations and the total length of the PAO1 genome, a Fisher's Exact Test was 450 performed using the fisher.test function in R with a "two sided" alternative hypothesis and a 451 significance threshold of 0.001. 452
Construction of point mutations in PAO1 pmrB 453
Point mutants in PAO1 were constructed using the protocol described in (46) with minor 454 modifications. pEX18Gm was used instead of pEX18Tc. Allelic exchange vectors (Table 4)  455 were made using Gibson Assembly® Master Mix (New England BioLabs) with primers listed in 456 Table 4 . Mutant pmrB alleles were amplified from the respective bioreactor end point isolate 457 containing the mutation. Electroporation of the constructed plasmid into PAO1 was done at room 458 temperature using a 2mm gap electroporation cuvette at 2.2 kV as described previously (46). 459 Electroporated cells were spread on BHI + 60 mg/l gentamicin (Gm) plates and incubated at 460 37⁰C for 2-3 days. Gm resistant colonies were colony purified on BHI + Gm60 plates and single 461 colonies were streaked on no salt LB (NSLB) + 15% sucrose plates and incubated at 30⁰C for 462 sucrose counterselection. Sucrose resistant colonies were tested for Gm sensitivity and for 463 colonies that were Gm sensitive and sucrose resistant, the pmrB gene was amplified and 464 sequenced using Sanger sequencing to determine presence of the point mutation. 465
Growth curves 466
Overnight cultures were prepared in LB broth in biological triplicate. Optical densities were 467 measured and normalized to 0.05. 96 well polypropylene plates were used for growth curves. 468
Each well was filled with 100 µl CA-MHB and a colistin gradient was set up for concentrations 469 ranging from 0 to 64 mg/l. Each well was inoculated with 1 µl of the OD normalized culture and 470 growth was measured in each well using a BioTek Epoch2 microplate reader at 37⁰C for 24 471 hours with optical density being measured at 5-minute intervals. The OD of plain CA-MHB 472 (blank reading) was subtracted from the OD of the samples at every time point. Exponential 473 smoothing was applied to each data series to account for the noise in the OD measurements due 474 to clumping and biofilm formation in the wells. The final graph of OD versus time was plotted 475 using the average of 3 biological replicates with standard deviation. Doubling times were 476 calculated in the OD600 interval 0.2 -0.4. 477
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